← Back to Analyst Consensus 
SLNO Hold
SOLENO THERAPEUTICS INC
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | downgrade | Overweight → Equal-Weight | — | 54% |
| Apr 8, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Apr 7, 2026 | TD Cowen | downgrade | Buy → Hold | — | 54% |
| Apr 7, 2026 | Wolfe Research | downgrade | Outperform → Peer Perform | — | 53% |
| Apr 6, 2026 | Cantor Fitzgerald | downgrade | Overweight → Neutral | — | 50% |
| Mar 18, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Mar 4, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Feb 27, 2026 | Wells Fargo | maintain | Overweight → Overweight | $110 | 54% |
| Feb 26, 2026 | TD Cowen | maintain | Buy → Buy | $85 | 54% |
| Jan 20, 2026 | Wells Fargo | maintain | Overweight → Overweight | $114 | 54% |
| Jan 20, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $120 | 44% |
| Nov 18, 2025 | Wolfe Research | initiate | — → Outperform | $75 | 53% |
| Nov 5, 2025 | Wells Fargo | maintain | Overweight → Overweight | $106 | 54% |
| Aug 27, 2025 | Guggenheim | reiterate | Buy → Buy | $106 | 52% |
| Aug 20, 2025 | Wells Fargo | initiate | — → Overweight | $123 | 54% |
| Aug 18, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $110 | 44% |
| Aug 7, 2025 | Guggenheim | maintain | Buy → Buy | $106 | 52% |
| Aug 7, 2025 | Oppenheimer | maintain | Outperform → Outperform | $110 | 52% |
| Jul 11, 2025 | Baird | maintain | Outperform → Outperform | $121 | 55% |
| May 8, 2025 | Guggenheim | maintain | Buy → Buy | $97 | 52% |
| May 8, 2025 | Baird | maintain | Outperform → Outperform | $105 | 55% |
| Apr 24, 2025 | Piper Sandler | maintain | Overweight → Overweight | $145 | 54% |
| Apr 15, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $100 | 44% |
| Mar 31, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $100 | 44% |
| Mar 28, 2025 | Stifel | maintain | Buy → Buy | $108 | 53% |
| Mar 28, 2025 | Guggenheim | maintain | Buy → Buy | $81 | 52% |
| Mar 27, 2025 | Laidlaw & Co. | maintain | Buy → Buy | $105 | 20% |
| Mar 27, 2025 | Baird | maintain | Outperform → Outperform | $102 | 55% |
| Mar 27, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $123 | 50% |
| Mar 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $70 | 44% |
| Dec 2, 2024 | Baird | reiterate | Outperform → Outperform | $72 | 55% |
| Dec 2, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $70 | 44% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $70 | 44% |
| Oct 28, 2024 | Oppenheimer | maintain | Outperform → Outperform | $73 | 52% |
| Aug 12, 2024 | Oppenheimer | maintain | Outperform → Outperform | $65 | 52% |
| Jul 31, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $67 | 50% |
| May 13, 2024 | Oppenheimer | maintain | Outperform → Outperform | $59 | 52% |
| May 10, 2024 | Baird | initiate | — → Outperform | $72 | 55% |
| Feb 5, 2024 | Piper Sandler | initiate | — → Overweight | $93 | 54% |
| Jan 23, 2024 | Stifel | initiate | — → Buy | $63 | 53% |
| Jan 2, 2024 | Oppenheimer | maintain | Outperform → Outperform | $47 | 52% |
| Sep 26, 2023 | Cantor Fitzgerald | maintain | Overweight → Overweight | $35 | 50% |
| Sep 15, 2023 | Oppenheimer | maintain | Outperform → Outperform | $14 | 52% |
| Aug 31, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $19 | 50% |
| Jul 11, 2023 | Cantor Fitzgerald | initiate | — → Overweight | $19 | 50% |
| May 25, 2023 | Oppenheimer | reiterate | — → Outperform | $8 | 52% |
| Mar 24, 2023 | Oppenheimer | reiterate | — → Outperform | $8 | 52% |
Price Target Trend
Apr 1, 2026 Latest: $53 Jul 18, 2026
EPS Estimates
+1q $1.06
Lo: $0.78 Hi: $1.55
8 analysts 0q $0.93
Lo: $0.78 Hi: $1.26
8 analysts +1y $6.06
Lo: $3.61 Hi: $9.92
7 analysts 0y $3.89
Lo: $2.69 Hi: $5.55
8 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days